Canada markets closed

BioCardia, Inc. (BCDA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.7600+0.0400 (+2.33%)
At close: 04:00PM EST
1.7900 +0.03 (+1.70%)
After hours: 06:18PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close1.7200
Open1.7790
Bid1.7000 x 800
Ask1.8000 x 3200
Day's Range1.6500 - 1.8600
52 Week Range1.6500 - 5.4800
Volume127,582
Avg. Volume147,496
Market Cap29.693M
Beta (5Y Monthly)1.43
PE Ratio (TTM)N/A
EPS (TTM)-0.7610
Earnings DateMar. 28, 2022 - Apr. 01, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.63
  • GlobeNewswire

    BioCardia Announces Participation at the Upcoming Digital Medicine & Medtech Showcase and the H.C. Wainwright BioConnect Virtual Conference

    SUNNYVALE, Calif. , Jan. 10, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and respiratory diseases, today announced it will be delivering virtual presentations during two investor meetings: The H.C. Wainwright BioConnect Virtual Conference taking place on January 10-13The Biotech Showcase taking place January 10-12 Dr. Peter Altman and Mr. David McClung, CEO and CFO of BioCardi

  • GlobeNewswire

    BioCardia Establishes New Manufacturing Facility to Enable Its Cell Therapy Product Candidates

    Facility Being Built Out to Support CardiAMP Cell Therapy Systems, Allogeneic NK1R+ MSC and Biotherapeutic Delivery Device Manufacturing for Clinical Trials of Multiple Programs and Early Commercial ActivitiesSAN CARLOS, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that it has entered into a long-term lease for a new facility in Sunnyvale,

  • GlobeNewswire

    BioCardia Reports Third Quarter 2021 Financial Results and Business Highlights

    SAN CARLOS, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the third quarter of 2021 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2021 with the Securities and Exchange Commission. Q3 and Recent Business Highlights: CardiAMP® Cell Therapy for ischemic heart failure (BCDA-01